Suppliers / Zhejiang Chiral Medicine Chemicals

Zhejiang Chiral Medicine Chemicals

China 3 employees Updated 9 July 2026

Zhejiang Chiral Medicine Chemicals is an API manufacturer based in China. It holds 4 active US drug master files and 6 valid CEPs across a filed portfolio of 4 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 14 March 2025 as VAI.

4
active US DMFs
6
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
6 of 6 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 14 March 2025 VAI US FDA
  • 12 September 2019 VAI US FDA
  • 13 October 2017 NAI US FDA
  • 11 August 2016 VAI US FDA
  • 29 January 2013 VAI US FDA
  • 19 August 2011 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Hangzhou, China Not on file
China, China 3003878169

What they file, and where

Molecule Regulators Docs
Carbidopa EDQM, US FDA 3
Etodolac EDQM, SFDA (Saudi Arabia), US FDA 3
Gabapentin EDQM, SFDA (Saudi Arabia), US FDA 3
Methyldopa EDQM, US FDA 3

Also appears on these molecule pages

Carbidopa API Gabapentin API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Zhejiang Chiral Medicine Chemicals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 14 March 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates